ORMP Oramed Pharmaceuticals Inc. - Common Stock
NASDAQ · Pharmaceuticals · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 10, 2026ORMP Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
ORMP Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
| Ex-Datum | Split | Typ |
|---|---|---|
| 23. Januar 2013 | 1-for-12 | Umgekehrt |
Über Oramed Pharmaceuticals Inc. - Common Stock Unternehmensübersicht von Wikipedia
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ORMP | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | 0.05-Jahres-Durchschnitt ≈0.1 | ≈0.1 | · | · | |
| P/S | 0.15-Jahres-Durchschnitt ≈100.5 | ≈100.5 | · | · | |
| K/B (MRQ) | 0.65-Jahres-Durchschnitt ≈1.4 | ≈1.4 | 1.2 | Unterbewertet | |
| Kurs / FCF (TTM) | -35.65-Jahres-Durchschnitt ≈-12.6 | ≈-12.6 | · | · | |
| Kurs / Cashflow (TTM) | -35.65-Jahres-Durchschnitt ≈-12.8 | ≈-12.8 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 0.05-Jahres-Durchschnitt ≈1.2 | ≈1.2 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ORMP | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Gross Margin (Bruttogewinnmarge) | 0.65% | · | · | · | |
| Operating Margin (Betriebsgewinnmarge) | -754.4%5-Jahres-Durchschnitt ≈-1144.4% | ≈-1144.4% | -12.4% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -754.4%5-Jahres-Durchschnitt ≈-1144.4% | ≈-1144.4% | 2.5% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | 3766.2% | · | 38.2% | Spitzenklasse | |
| Net Profit Margin (Nettogewinnmarge) | 3202.5%5-Jahres-Durchschnitt ≈739.2% | ≈739.2% | 30.4% | Spitzenklasse | |
| ROA | 33.2%5-Jahres-Durchschnitt ≈4.6% | ≈4.6% | -1.5% | Spitzenklasse | |
| ROE | 37.0%5-Jahres-Durchschnitt ≈5.6% | ≈5.6% | -7.6% | Spitzenklasse | |
| ROIC | -6.4% | · | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ORMP | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 5.05-Jahres-Durchschnitt ≈12.5 | ≈12.5 | 9.6 | Unterdurchschnittlich | |
| Quick Ratio | 2.75-Jahres-Durchschnitt ≈1.5 | ≈1.5 | 3.1 | Unterdurchschnittlich |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | ORMP | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -50.4% | · | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -9.6% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ORMP | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.4 | Schwach |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Jan 16, 2026 | $0,25 | USD | ≈6.8% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 12, 2026 | $1.84 | $0.44 | 319.5% |
| 31. Dezember 2025 | $0.24 | $0.00 | — | |
| 30. September 2025 | $1.12 | $-0.04 | 2845.1% | |
| 30. Juni 2025 | $0.31 | $-0.04 | 859.8% | |
| 31. März 2025 | $-0.19 | $-0.01 | -1762.7% | |
| 31. Dezember 2024 | $0.00 | $-0.03 | 100.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Cost of Revenue | $2M | · | · | · | · | · | $90.0K | $-86.0K | $187.0K | |
| Gross Profit | $13.0K | · | · | · | · | · | · | · | · | |
| R&D Expense | $6M | $6M | $9M | $28M | · | $10M | $14M | $12M | $10M | |
| SG&A Expense | $9M | $6M | $8M | $14M | · | $4M | $4M | $4M | $3M | |
| Operating Income | $-15M | $-13M | $-16M | $-41M | · | $-12M | $-15M | $-14M | $-11M | |
| Interest Expense | · | · | $2M | · | · | · | · | · | · | |
| Interest Income | · | · | $10.0K | · | · | · | · | · | · | |
| Other Non-op | $-606.0K | $-27.0K | $13.3K | $3M | · | · | · | · | · | |
| Pretax Income | $75M | $-16M | $5M | $-38M | · | $-12M | $-14M | $-13M | $-10M | |
| Income Tax | $11M | $3M | · | $100.0K | · | · | $300.0K | · | $400.0K | |
| Net Income | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| EPS (Basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| EPS (Diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| Shares (Basic) | 41,402,997 | 40,850,446 | 40,315,068 | 38,997,649 | · | · | · | · | · | |
| Shares (Diluted) | 42,418,644 | 40,850,446 | 40,566,901 | 38,997,649 | · | · | · | · | · | |
| EBITDA | $-15M | · | $-16M | $-41M | · | $-12M | $-15M | · | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $54M | $9M | $40M | · | $19M | $3M | $5M | $4M | |
| Short-term Investments | $5M | $3M | · | · | $8M | $3M | · | $5M | · | |
| Prepaid Expense | $3M | $1M | $537.0K | $1M | · | $611.0K | $1M | $574.0K | · | |
| Current Assets | $133M | $143M | $163M | $157M | $148M | $41M | $33M | $31M | · | |
| PP&E (Net) | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | · | |
| Other Non-current Assets | $44.0K | $32.0K | $27.0K | · | · | · | · | · | · | |
| Total Assets | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Accounts Payable | $443.0K | $789.0K | $551.0K | $4M | $5M | $2M | $3M | $2M | · | |
| Accrued Liabilities | $1M | $402.0K | $605.0K | · | · | · | · | · | · | |
| Short-term Debt | $652.0K | $329.0K | $51M | · | · | · | $3M | $2M | · | |
| Current Liabilities | $19M | $6M | $53M | $6M | $7M | $5M | $5M | $5M | · | |
| Capital Leases | $540.0K | $156.0K | $342.0K | $647.0K | $370.0K | $31.0K | · | · | · | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | $60.0K | $63.0K | · | · | $211.0K | $271.0K | $313.0K | · | |
| Long-term Debt | · | · | · | $25.0K | $12M | · | $10M | $11M | · | |
| Total Debt | · | · | $51M | · | · | · | $3M | · | · | |
| Common Stock | $472.0K | $480.0K | $485.0K | $476.0K | $459.0K | $284.0K | $208.0K | $207.0K | · | |
| Paid-in Capital | · | · | · | $314M | $293M | $125M | · | · | · | |
| Retained Earnings | $-123M | $-177M | $-158M | $-163M | $-127M | $-93M | $-81M | $-69M | · | |
| AOCI | · | · | · | · | · | · | · | $702.0K | · | |
| Stockholders' Equity | $200M | $145M | $164M | $152M | $166M | $33M | $19M | $31M | $19M | |
| Liabilities + Equity | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Shares Outstanding | 39,275,006 | 39,920 | 40,339,000 | 39,564,000 | 38,158 | 23,675,530 | 17,383,359 | 17,369,875 | · |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | $4M | $12M | · | $465.0K | $808.0K | $2M | $2M | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-8M | $-10M | $-28M | · | $-12M | $-13M | $-15M | $-6M | |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | · | $82.0K | $15.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $5M | $106M | $-73M | $30M | · | $5M | $11M | $-7M | $4M | |
| Stock Issued | · | · | $2M | $12M | · | · | · | · | · | |
| Stock Repurchased | $5M | $2M | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | $2M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-5M | $-52M | $52M | $11M | · | $24M | · | $23M | $2M | |
| Net Change in Cash | $-8M | $45M | $-31M | $13M | · | $16M | $-2M | $1M | $62.0K | |
| Taxes Paid | · | $2M | · | $2M | · | · | $300.0K | · | $400.0K | |
| Free Cash Flow | $-9M | · | $-11M | $-28M | · | $-13M | $-13M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | · | · | · | · | · | |
| Operating Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| Net Margin | 3202.5% | · | 412.3% | -1397.1% | · | -424.8% | -531.1% | · | · | |
| Pretax Margin | 3766.2% | · | 379.7% | · | · | -424.8% | -520.0% | · | · | |
| EBITDA Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| ROA | 33.2% | · | 2.9% | -22.2% | · | -29.0% | -35.0% | · | · | |
| ROE | 37.0% | · | 3.5% | -23.7% | · | -47.0% | -70.1% | · | · | |
| ROIC | -6.4% | · | · | · | · | · | -67.6% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · | 8.9 | 6.3 | · | · | |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · | 5.0 | 1.3 | · | · | |
| Debt / Equity | · | · | 0.3 | · | · | · | 0.1 | · | · | |
| Interest Coverage | · | · | -7.7 | · | · | · | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | · | 0.1 | 0.1 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $5.09 | · | $4.06 | $3.84 | · | $1.39 | $1.12 | · | · | |
| Revenue / Share | $0.05 | · | $0.03 | $0.07 | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | · | $-0.25 | $-0.72 | · | · | · | · | · | |
| Cash / Share | $1.17 | · | $0.22 | · | · | $0.81 | $0.19 | · | · | |
| Dividend Paid / Share | $0.25 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -50.4% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $3M | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Net Income TTM | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| Market Cap | $112M | · | $93M | $476M | · | $83M | $58M | · | · | |
| Enterprise Value | · | · | $77M | · | · | · | $53M | · | · | |
| P/E | 1.9 | -5.0 | 16.5 | -12.8 | · | · | · | · | · | |
| P/S | 56.0 | · | 69.5 | 176.1 | · | 30.5 | 21.4 | · | · | |
| P/B | 0.6 | · | 0.6 | 3.1 | · | 2.5 | 3.0 | · | · | |
| P / Tangible Book | 0.6 | 0.7 | 0.6 | 3.1 | · | 2.5 | · | · | · | |
| P / Cash Flow | -12.2 | · | -9.1 | -17.0 | · | -6.6 | -4.5 | · | · | |
| P / FCF | -12.2 | · | -8.8 | -16.8 | · | -6.6 | -4.5 | · | · | |
| EV / EBITDA | · | · | -4.9 | · | · | · | -3.6 | · | · | |
| EV / FCF | · | · | -7.3 | · | · | · | -4.1 | · | · | |
| EV / Revenue | · | · | 57.8 | · | · | · | 19.8 | · | · | |
| Earnings Yield | 52.6% | -19.8% | 6.1% | -7.8% | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | · | · | $2M | · | · | · | · | $0 | · | $674.0K | $666.0K | $681.0K | $682.0K | |
| Cost of Revenue | · | · | $0 | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Gross Profit | · | · | $0 | · | · | $13.0K | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | · | $2M | $2M | $1M | $1M | $2M | $1M | $2M | $1M | $1M | $2M | $957.0K | $2M | $4M | $7M | $5M | |
| SG&A Expense | $3M | $2M | $4M | $1M | $1M | $2M | $2M | $847.0K | $2M | $2M | $2M | $3M | $2M | $1M | $3M | $3M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $11.0K | |
| Operating Income | $-3M | $-4M | $-6M | $-2M | $-2M | $-4M | $-4M | $-3M | $-3M | $-3M | $-4M | $-3M | $-4M | $-5M | $-10M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $592.0K | · | $826.0K | · | · | · | · | |
| Other Non-op | $-4.0K | $-100.0K | $-74M | $61M | · | $-143.0K | $-2M | $-15M | $14M | $4M | $-4M | $435.0K | $2M | $2M | $1M | $1M | |
| Pretax Income | $102M | $49M | $10M | $59M | $13M | $-7M | $-10M | $-19M | $11M | $2M | $13M | $-3M | $-1M | · | $-9M | $-7M | |
| Income Tax | $23M | $11M | $-212.0K | $11M | $-126.0K | $584.0K | $416.0K | $1M | $2M | · | · | · | · | · | $0 | $100.0K | |
| Net Income | $78M | $38M | $10M | $48M | $13M | $-8M | $-10M | $-20M | $9M | $2M | $13M | $-3M | $-1M | $-3M | $-8M | $-7M | |
| EPS (Basic) | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| EPS (Diluted) | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| Shares (Basic) | 41,040,479 | 40,773,866 | · | 41,756,301 | 41,743,486 | 41,228,782 | · | 40,896,845 | 40,959,759 | 40,835,953 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| Shares (Diluted) | 42,501,252 | 41,970,186 | · | 42,774,504 | 42,609,425 | 41,228,782 | · | 40,896,845 | 41,591,007 | 41,564,007 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| EBITDA | $-3M | $-4M | · | $-2M | $-2M | $-4M | · | $-3M | $-3M | $-3M | · | $-3M | $-4M | $-5M | · | $-8M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $13M | $46M | $52M | $16M | · | $54M | · | $10M | $19M | · | · | · | · | $40M | · | |
| Short-term Investments | $846.0K | $5M | $5M | $5M | $2M | $4M | $3M | $57M | $66M | $78M | · | $49.4K | $943.0K | $2M | · | $5M | |
| Prepaid Expense | $2M | $2M | $3M | $1M | $1M | $832.0K | $1M | $474.0K | $533.0K | $501.0K | $537.0K | $666.0K | $769.0K | · | $1M | · | |
| Current Assets | $53M | $68M | $133M | $136M | $99M | $131M | $143M | $143M | $153M | $177M | $163M | $176M | $151M | $155M | $157M | $160M | |
| PP&E (Net) | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K | $765.0K | $819.0K | $873.0K | $923.0K | $945.0K | $977.0K | $815.0K | $535.0K | |
| Other Non-current Assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | · | · | · | $27.0K | · | · | · | · | · | |
| Total Assets | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Accounts Payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | $5M | $3M | $1M | $551.0K | $3M | $828.0K | $4M | $4M | $4M | |
| Accrued Liabilities | $1M | $1M | $1M | $585.0K | $841.0K | $800.0K | $402.0K | · | · | · | $605.0K | · | · | · | · | · | |
| Short-term Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | $51M | $75M | $3.0K | $1.0K | · | · | |
| Current Liabilities | $11M | $11M | $19M | $6M | $4M | $5M | $6M | $5M | $4M | $34M | $53M | $78M | $1M | $5M | $6M | $7M | |
| Capital Leases | $484.0K | $493.0K | $540.0K | $589.0K | $648.0K | $120.0K | $156.0K | $186.0K | $236.0K | $272.0K | $342.0K | $389.0K | $488.0K | $564.0K | $647.0K | $672.0K | |
| Deferred Tax | $40M | $18M | $8M | $8M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $60.0K | $60.0K | $60.0K | · | $63.0K | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $75M | · | · | · | $5M | |
| Total Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | · | $75M | $3.0K | $1.0K | · | · | |
| Common Stock | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K | $488.0K | $487.0K | $485.0K | $484.0K | $484.0K | $481.0K | $476.0K | $470.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | $319M | $317M | · | $308M | |
| Retained Earnings | $-7M | $-85M | $-123M | $-123M | $-171M | $-184M | $-177M | $-166M | $-147M | $-156M | $-158M | $-171M | $-168M | $-166M | $-163M | $-155M | |
| Stockholders' Equity | $317M | $238M | $200M | $203M | $155M | $141M | $146M | $156M | $177M | $167M | $164M | $149M | $152M | $151M | $152M | $154M | |
| Liabilities + Equity | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Shares Outstanding | 41,314,211 | 40,926,081 | 39,275,006 | 40,838,226 | 40,845,087 | 40,850,455 | 39,919,545 | 40,209,575 | 40,628,924 | 40,519,160 | 40,338,979 | 40,282,688 | 40,219,396 | 39,969,979 | 39,563,888 | 39,113,236 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $2M | $719.0K | $800.0K | $2M | $1M | $301.0K | $1M | $1M | $1M | $852.0K | $2M | $173.0K | $3M | $3M | |
| Deferred Tax | $22M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-200.0K | $-3M | $-466.0K | $-2M | $-4M | $-4M | $-2M | $-7M | $2M | $-1M | $-1M | $-694.0K | $-3M | $-6M | $-8M | $-2M | |
| CapEx | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K | $20.0K | $199.0K | $308.0K | $121.0K | |
| Investing Cash Flow | $4M | $-19M | $-2M | $38M | $-55M | $24M | $15M | $-34M | $95M | $30M | $30M | $-75M | $-15M | $-13M | $11M | $1M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-2.0K | $0 | $2M | $4M | $-3M | |
| Stock Repurchased | · | · | $4M | $361.0K | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | $78.0K | $10M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-2M | $-10M | $-4M | $-361.0K | · | · | $-1M | $-1M | $-31M | $-19M | $-25M | $75M | $0 | $2M | $4M | $4M | |
| Net Change in Cash | $2M | $-33M | $-6M | $36M | $-59M | $20M | $12M | $-43M | $66M | $10M | $4M | $-1M | $-17M | $-16M | $7M | $3M | |
| Taxes Paid | · | · | · | $-7M | · | · | · | · | · | · | · | $527.0K | $3M | $308.0K | · | $167.0K | |
| Free Cash Flow | · | $-3M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-6M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 0.65% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| Net Margin | · | · | · | · | · | -382.1% | · | · | · | · | · | · | -177.2% | -542.2% | · | -1063.5% | |
| Pretax Margin | · | · | · | · | · | -352.9% | · | · | · | · | · | · | · | · | · | -1048.8% | |
| EBITDA Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| ROA | 29.4% | 18.4% | · | 25.1% | 7.7% | -4.3% | · | -9.9% | 5.4% | 0.85% | · | -1.6% | -0.75% | -2.2% | · | -5.9% | |
| ROE | 33.1% | 20.2% | · | 26.9% | 8.0% | -5.0% | · | -12.8% | 5.6% | 0.97% | · | -2.1% | -0.78% | -2.3% | · | -6.5% | |
| ROIC | -0.67% | -1.2% | · | -0.97% | -1.6% | -3.5% | · | -2.1% | -1.5% | · | · | · | · | · | · | -5.4% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 6.5 | · | 22.2 | 26.8 | 23.9 | · | 27.1 | 41.1 | 5.3 | · | 2.2 | 141.5 | 31.2 | · | 24.5 | |
| Quick Ratio | 1.5 | 1.7 | · | 9.3 | 4.8 | 0.7 | · | 10.9 | 20.4 | 2.9 | · | 0.0 | 0.9 | 0.5 | · | 0.8 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.2 | · | 0.5 | 0.0 | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -5.0 | · | -3.5 | · | · | · | · |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.68 | $5.82 | · | $4.98 | $3.78 | $3.45 | · | $3.89 | $4.36 | $4.11 | · | $3.70 | $3.77 | $3.78 | · | $3.93 | |
| Revenue / Share | · | · | · | · | · | $0.05 | · | · | · | · | · | · | $0.02 | $0.02 | · | $0.02 | |
| Cash Flow / Share | · | $-0.07 | · | · | · | $-0.09 | · | · | · | $-0.04 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.37 | $0.32 | · | $1.28 | $0.39 | · | · | · | $0.25 | $0.46 | · | · | · | · | · | · | |
| EPS (TTM) | $4.13 | $2.60 | · | $0.99 | $-0.62 | $-0.71 | · | $0.11 | $0.51 | $0.26 | · | $-1.85 | $-1.59 | $-1.29 | · | · |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Net Income TTM | $175M | $110M | · | $44M | $-24M | $-28M | · | $4M | $20M | $10M | · | $-16M | $-20M | $-29M | · | $-36M | |
| Market Cap | $199M | $139M | · | $108M | $92M | $87M | · | $98M | $104M | $118M | · | $105M | $144M | $87M | · | $253M | |
| Enterprise Value | · | · | · | $51M | $74M | · | · | · | · | $54M | · | · | · | · | · | · | |
| P/E | 1.2 | 1.3 | · | 2.7 | -3.6 | -3.0 | · | 22.2 | 5.0 | 11.2 | · | -1.4 | -2.3 | -1.7 | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 38.9 | 53.3 | 32.2 | · | 94.0 | |
| P/B | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Tangible Book | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Cash Flow | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.2 | · | · | · | -15.7 | · | · | |
| Earnings Yield | 85.9% | 76.5% | · | 37.5% | -27.6% | -33.2% | · | 4.5% | 19.8% | 8.9% | · | -70.9% | -44.4% | -59.2% | · | · | |
| Payout Ratio | · | 27.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $2M | · | $1M | $3M | · |
| Bruttogewinnmarge % | 0.65% | · | · | · | · |
| Betriebsgewinnmarge % | -754.4% | · | -1176.8% | -1502.0% | · |
| Nettoergebnis | $64M | $-19M | $5M | $-37M | · |
| Verwässerte EPS | $1.50 | $-0.48 | $0.14 | $-0.94 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | · | · | 0.3 | · | · |
| Liquiditätsgrad | 7.0 | · | 3.1 | 27.3 | · |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-9M | · | $-11M | $-28M | · |
Institutionelle Eigentümer (13F) 87 Einreicher · $85.5M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 30 (+13 vs. Vorquartal) | 8 (0 vs. Vorquartal) | 21 (+2 vs. Vorquartal) | 19 (+4 vs. Vorquartal) | +3.6M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | $18.328.697 | 3.810.540 | 21,43% | Aktien |
| Aquamarine Financial (Cayman) Ltd | $12.083.562 | 2.512.175 | 14,13% | Aktien |
| Gem Investment Advisors, LLC | $9.614.238 | 1.998.802 | 11,24% | Aktien |
| BlackRock, Inc. | $7.735.015 | 1.608.111 | 9,04% | Aktien |
| Murchinson Ltd. | $6.206.314 | 1.290.294 | 7,26% | Aktien |
| SB Capital Management Inc | $5.415.000 | 1.900.000 | 6,33% | Aktien |
| BML Capital Management, LLC | $4.166.754 | 866.269 | 4,87% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.783.249 | 578.638 | 3,25% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $2.408.318 | 500.690 | 2,82% | Aktien |
| GOLDMAN SACHS GROUP INC | $1.218.339 | 253.293 | 1,42% | Aktien |
| STATE STREET CORP | $1.164.501 | 242.100 | 1,36% | Aktien |
| Rathbones Group PLC | $1.120.816 | 233.018 | 1,31% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.105.732 | 229.882 | 1,29% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $973.782 | 202.609 | 1,14% | Aktien |
| NORTHERN TRUST CORP | $889.465 | 184.920 | 1,04% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $884.078 | 183.800 | 1,03% | Aktien |
| WELLS FARGO & COMPANY/MN | $798.458 | 166.000 | 0,93% | Aktien |
| BANK OF AMERICA CORP /DE/ | $724.838 | 150.694 | 0,85% | Aktien |
| STRS OHIO | $643.578 | 133.800 | 0,75% | Aktien |
| JANE STREET GROUP, LLC | $545.209 | 113.349 | 0,64% | Aktien |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $495.247 | 102.962 | 0,58% | Aktien |
| MARSHALL WACE, LLP | $490.393 | 101.953 | 0,57% | Aktien |
| Hillsdale Investment Management Inc. | $429.533 | 89.300 | 0,50% | Aktien |
| RITHOLTZ WEALTH MANAGEMENT | $405.709 | 84.347 | 0,47% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $402.280 | 83.634 | 0,47% | Aktien |
| Bank of New York Mellon Corp | $381.217 | 79.255 | 0,45% | Aktien |
| UBS Group AG | $325.498 | 67.671 | 0,38% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $287.518 | 59.775 | 0,34% | Aktien |
| XTX Topco Ltd | $240.130 | 49.923 | 0,28% | Aktien |
| Nuveen, LLC | $223.203 | 46.404 | 0,26% | Aktien |
| MORGAN STANLEY | $208.547 | 43.357 | 0,24% | Aktien |
| CITADEL ADVISORS LLC | $199.927 | 41.565 | 0,23% | Aktien |
| DEUTSCHE BANK AG\ | $159.682 | 33.198 | 0,19% | Aktien |
| PRELUDE CAPITAL MANAGEMENT, LLC | $157.350 | 32.713 | 0,18% | Aktien |
| BAILARD, INC. | $156.219 | 32.478 | 0,18% | Aktien |
| RHUMBLINE ADVISERS | $147.281 | 30.621 | 0,17% | Aktien |
| ALGERT GLOBAL LLC | $139.288 | 28.958 | 0,16% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $121.246 | 25.207 | 0,14% | Aktien |
| CITADEL ADVISORS LLC | $120.250 | 25.000 | 0,14% | Kaufoption |
| Invesco Ltd. | $119.052 | 24.751 | 0,14% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $107.263 | 22.300 | 0,13% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $105.151 | 21.861 | 0,12% | Aktien |
| PNC Financial Services Group, Inc. | $101.972 | 21.200 | 0,12% | Aktien |
| Redwood Family Wealth LLC | $99.783 | 20.745 | 0,12% | Aktien |
| Sage Capital Management, LLC | $86.474 | 17.977 | 0,10% | Aktien |
| CITIGROUP INC | $76.037 | 15.808 | 0,09% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $75.378 | 15.671 | 0,09% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $67.811 | 14.098 | 0,08% | Aktien |
| JPMORGAN CHASE & CO | $65.693 | 14.158 | 0,08% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $61.650 | 12.817 | 0,07% | Aktien |
Aktivisten & 5%+-Eigentümer 9 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 22. Juli 2026 | 3,30% | Änderung | · | SEC |
| Nadav Kidron ×8 Einreichungen | 28. August 2025 | 7,60% | Änderung | · | SEC |
| Regals Capital Management LP, Regals Fund LP, David M. Slager ×2 Einreichungen | 20. Juli 2018 | · | Erste Einreichung | · | SEC |
| Hefei Tianhui Incubator of Technologies Co., Ltd | 6. Januar 2016 | · | Erste Einreichung | · | SEC |
| Leonard Sank | 15. Dezember 2014 | · | Erste Einreichung | Passive Anlage | SEC |
| Miriam Kidron ×2 Einreichungen | 3. Februar 2014 | · | Erste Einreichung | · | SEC |
| Zeev Bronfeld | 6. März 2006 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Juni 2004 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Juni 2004 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 30 Insider · 13 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO | 24. September 2026 D | 4.140.505 | 0 | 0 | $0 |
| Avraham Gabay | Chief Financial Officer | 1. Oktober 2026 S | 861.076 | 0 | 2 | $-421.054 |
| David Silberman | Chief Financial Officer | 4. Januar 2024 A | 366.500 | 0 | 0 | $0 |
| Hilla Eisenberg | CFO, Treasurer and Secretary | 26. Februar 2019 A | · | 0 | 0 | $0 |
| Yifat Hen Zommer | CFO, Treasurer and Secretary | 30. Juni 2017 A | 46.560 | 0 | 0 | $0 |
| Chaime Orlev | CFO, Treasurer and Secretary | 12. Oktober 2008 A | · | 0 | 0 | $0 |
| Joshua Hexter | COO & CBO | 1. Oktober 2026 S | 1.328.130 | 0 | 2 | $-746.320 |
| Miriam Kidron | Chief Scientific Officer | 24. September 2026 D | 1.550.554 | 0 | 0 | $0 |
| Netanel Derovan | Chief Legal Officer | 26. Mai 2023 A | 149.500 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3. Januar 2023 S | 126.143 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3. Januar 2022 A | 109.468 | 0 | 0 | $0 |
| Mark Daniel Hasleton | VP Business Development | 26. Februar 2019 A | · | 0 | 0 | $0 |
| Ronald Edward Law | Chief Strategy Officer | 20. März 2017 A | · | 0 | 0 | $0 |
| Yehuda Reznick | Direktor | 31. Dezember 2025 A | 105.180 | 0 | 0 | $0 |
| Daniel Aghion | Direktor | 31. Dezember 2025 A | 113.441 | 0 | 0 | $0 |
| Benjamin Shapiro | Direktor | 31. Dezember 2025 A | 123.220 | 0 | 0 | $0 |
| Arie Mayer | Direktor | 31. Dezember 2025 A | 168.009 | 0 | 0 | $0 |
| Leonard Sank | Direktor | 5. Juni 2025 A | 134.531 | 0 | 0 | $0 |
| Yadin Rozov | Direktor | 4. Januar 2024 A | 155.320 | 0 | 0 | $0 |
| Kevin Rakin | Direktor | 21. März 2022 S | 46.661 | 0 | 0 | $0 |
| Aviad Friedman | Direktor | 3. Januar 2022 G | 0 | 0 | 0 | $0 |
| Gao Xiaoming | Direktor | 8. Januar 2020 A | · | 0 | 0 | $0 |
| David Mark Slager | Direktor | 15. April 2019 A | 1.316.328 | 0 | 0 | $0 |
| Xiaopeng Li | Direktor | 2. August 2017 P | 206.350 | 0 | 0 | $0 |
| Harold Jacob | Direktor | 10. März 2016 S | 16.396 | 0 | 0 | $0 |
| Michael Berelowitz | Direktor | 9. Dezember 2015 S | 22.896 | 0 | 0 | $0 |
| Gerald M Ostrov | Direktor | 23. Februar 2015 A | 24.896 | 0 | 0 | $0 |
| REGALS CAPITAL MANAGEMENT LP | 10%-Eigentümer | 23. Dezember 2015 X | 1.186.823 | 0 | 0 | $0 |
| Zeev Bronfeld | 10%-Eigentümer | 27. September 2011 S | 5.808.517 | 0 | 0 | $0 |
| Michael Young | · | 27. Mai 2004 S | 0 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 13 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,04% | 117.335 SH | 11. September 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 7.007 SH | 2. Oktober 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29.637 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,00% | 16.237 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 622.970 SH | 11. September 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 40.483 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 4.523 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.536 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 3.431 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 196.765 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.480 SH | 19. August 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,00% | 4 NS | 31. Juli 2026 | N-PORT |
| IWN · iShares Trust | · | 316.654 SH | 11. September 2026 | Täglich |
ORMP Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
12-Monats-Kursziel
1 Analysten · 2026-09-29Mittelwert-Ziel $7.00 +55,9%
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.